Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002317 · ClinicalTrials.gov registry record · NA

A Study of Trimetrexate Plus Leucovorin in Children With Pneumocystis Carinii Pneumonia

A NA study of HIV Infections and Pneumonia, Pneumocystis Carinii, sponsored by U.S. Bioscience.

Completed
Registry status
NA
Development phase
1
Study location

NCT00002317 is a NA study of HIV Infections and Pneumonia, Pneumocystis Carinii that has completed, run by U.S. Bioscience. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002317, a NA study of HIV Infections and Pneumonia, Pneumocystis Carinii, has completed, sponsored by U.S. Bioscience.

COMPLETED
Registry status
NA
Development phase
1
Study location

Study Summary

To evaluate the safety and efficacy of trimetrexate glucuronate with leucovorin protection in pediatric patients with Pneumocystis carinii pneumonia (PCP) who are refractory to or have demonstrated severe or life-threatening toxicities to standard therapies (e.g., TMP/SMX or parenteral pentamidine).

Interventions

  • DRUG Leucovorin calcium
  • DRUG Trimetrexate glucuronate

Study Locations (1)

Pennsylvania

  • United States Bioscience Inc - West Conshohocken

Trial Details

FieldValue
Phase NA

Sponsor

U.S. Bioscience

5 total trials

What the Registry Record Tells You About NCT00002317

The ClinicalTrials.gov registry entry for NCT00002317 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is U.S. Bioscience, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Leucovorin calcium is the first listed.

NCT00002317 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00002317 about?

NCT00002317 is a clinical study titled "A Study of Trimetrexate Plus Leucovorin in Children With Pneumocystis Carinii Pneumonia". To evaluate the safety and efficacy of trimetrexate glucuronate with leucovorin protection in pediatric patients with Pneumocystis carinii pneumonia (PCP) who are refractory to or have demonstrated severe or life-threatening toxicities to standard therapies (e.g., TMP/SMX or parenteral pentamidine).

What is the current status of trial NCT00002317?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002317 study?

This clinical trial studies the following conditions: HIV Infections, Pneumonia, Pneumocystis Carinii.

What interventions are being tested in trial NCT00002317?

The interventions under investigation include: Leucovorin calcium (DRUG), Trimetrexate glucuronate (DRUG).

Who is sponsoring clinical trial NCT00002317?

This trial is sponsored by U.S. Bioscience, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002317 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.